RACK1 Inhibitors for Treatment of Viral Infections
Contracts Guide
Disclose Your Invention
MTA/CDA Assistance
COVID-19 Related Agreements
Main Campus Research
Office of Sponsored Research
Education Links
Connect with Industry
Technologies for Licensing
Industry Collaboration Opportunities
Research and Clinical Trials
Categories: “”Viruses, Chronic & Infectious Diseases”
Reference #: 2015-035
OTC Contact: Ruchika Nijhara Ph.D., MBA (Directory Information | Send a Message)
Description
Viruses require host factors to translate their transcripts and so targeting the host factor (s) offers an opportunity to develop broad spectrum anti-viral drugs. The receptor for Activated C Kinase I (RACK1) is one such host protein that some viruses use to translate their mRNAs using a viral mRNA secondary structure known as the Internal Ribosomal Entry Site (IRES). The present invention pertains to compounds and methods of treating infections from viruses containing a genome coding IRES by administering such RACK1 inhibitors that block IRES mediated translation of such viruses.
Applications
- Treating infections from viruses containing a genome having IRES including but not limited to hepatitis C (HCV), polio, Dengue, Cornaviruses, HIV and Herpes Simplex virus (HSV).
Advantages
- The strategy of targeting the host factor, instead of the virus directly, potentially circumvents the damaging effect of resistance developed by viruses after the prolonged use of anti-viral drugs.
Stage of Development
Proof of concept demonstrated in vitro. The lead compound did not demonstrate any major toxicity linked to RACK1 inhibition.
Inventors
Hemayet Ullah
Sivanesan Dakshanamurthy
Patent Status
Patent pending